Saurabh Zanwar

1/ Our call to action is out in @BloodAdvances! Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold. Global authors & global audience, including insurance & healthcare funders.

Why do many regulatory oncology phase III trials not accrue sufficient US patients? This issue came up repeatedly at today’s ODAC for belantamab for myeloma. And I can address it at least for myeloma. 1) In our healthcare system, opening a trial in a timely manner is a…

Solitary but not simple─SPMs demonstrate marked heterogeneity in outcomes. The emergence of molecular and cytogenetic data to guide personalised management is the foundational step to improving outcomes. ⁦@MayoMyeloma⁩ ⁦@VincentRK⁩ nature.com/articles/s4137…

Silence of the myeloma clones: GPRC5D epigenetic regulation | Blood | American Society of Hematology ashpublications.org/blood/article/…

Our findings are important and open a new understanding of biology and novel way of therapy @MayoCancerCare @WitzigLab JCI - Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma jci.org/articles/view/…

✨ I’m honored to share my story published by BlackDoctor.org: “How I Beat a Deadly Cancer Nobody Thought I Could Survive.” At just 25, I received a multiple myeloma diagnosis and was given only a few years to live. But I refused to accept that prognosis. Over the past…

FDA Eliminates REMS for Chimeric Antigen Receptor (CAR) T cell Immunotherapies. Pts now only need to remain close to CAR T facility for 2 weeks (no longer 4 weeks) and avoid driving for 2 weeks (no longer 8 weeks) following CAR T. Huge access improvement! fda.gov/vaccines-blood…

Major Regulatory Milestone in MM: In response to an application by I2TEAMM and @IMFmyeloma, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !! @VincentRK

Standardizing FISH testing in myeloma is critical to reduce lab to lab variability and misinterpretation. We propose guidelines for FISH panel design and reporting to align with the new IMS/IMWG risk stratification. @CG_Consortium @MayoMyeloma

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Check our long term follow up of earlier total therapy protocols in Arkansas @JAMAOnc @UAMSMyeloma #mmsm ➡️ jamanetwork.com/journals/jamao… ✅ With time limited therapy&median follow up of ~17 years of 1202 patients, we estimate one out of three patients are cured from their multiple…

And a new era of MRD-guided personalized therapy… @NEJM @TheIACH @COMyCongress @IUCTOncopole Congratulations @PerrotAurore nejm.org/doi/abs/10.105…

Join us in the education session today in S 102👇 Current and Future Directions of Immunotherapies in Multiple Myeloma Check the educational chapter: ascopubs.org/doi/10.1200/ED… Will discuss the role of quad therapy in newly diagnosed multiple myeloma #mmsm #ASCO25 @UAMSMyeloma…

#ASCO25 been great so far. Congratulations to our incredible fellows on their ASCO young investigator awards!Pictured here Dr. @SPremji7866 and Dr @RyanAugustinMD

Lots of great discussion at the poster. Many centers starting some type of mitigating strategy for patients with hyper-expansion of lymphocytes after #CiltaCel infusion. Will it help reduce incidence or severity of these late toxicities? Teaser for #ASH25

Delighted to share our latest publication on the impact of conditioning intensity in younger AML patients receiving dual T-cell depletion for GVHD prophylaxis. #Hematology #BMT @AhmedAlNughmush @Hans_BMTProgram doi.org/10.1111/ejh.14…

Excellent work and an important piece of data by @dr_arewah_bohra 👏👏Translating Peripheral blood flow data into meaningful thresholds aligning with the peripheral smear-based criteria for PCL. 1.2% CPCs by flow ≈ 5% CPCs by smear @MayoMyeloma

Thrilled that Dr. Saad Usmani @szusmani Chair of the myeloma program @MSKCancerCenter will receive the Giants of Cancer Care Award for Myeloma @OncLive tomorrow. #ASCO25 Congrats dear friend! Best wishes on behalf of all our myeloma colleagues. Cheers!